7SN1 image
Entry Detail
PDB ID:
7SN1
Keywords:
Title:
Structure of human SARS-CoV-2 neutralizing antibody C1C-A3 Fab
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-10-27
Release Date:
2021-12-08
Method Details:
Experimental Method:
Resolution:
1.47 Å
R-Value Free:
0.20
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:neutralizing antibody C1C-A3 Fab heavy chain
Chain IDs:A (auth: H)
Chain Length:250
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:neutralizing antibody C1C-A3 Fab light chain
Chain IDs:B (auth: L)
Chain Length:238
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation

Abstact

Many studies have examined the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants on neutralizing antibody activity after they have become dominant strains. Here, we evaluate the consequences of further viral evolution. We demonstrate mechanisms through which the SARS-CoV-2 receptor binding domain (RBD) can tolerate large numbers of simultaneous antibody escape mutations and show that pseudotypes containing up to seven mutations, as opposed to the one to three found in previously studied variants of concern, are more resistant to neutralization by therapeutic antibodies and serum from vaccine recipients. We identify an antibody that binds the RBD core to neutralize pseudotypes for all tested variants but show that the RBD can acquire an N-linked glycan to escape neutralization. Our findings portend continued emergence of escape variants as SARS-CoV-2 adapts to humans.

Legend

Protein

Chemical

Disease

Primary Citation of related structures